Cervical Cancer Vaccination In Jabalpur
Cervical Cancer Vaccination In Jabalpur
Cervical cancer is the fifth most common cancer in humans, the second most common cancer in women worldwide or the most common cancer cause of death in the developing countries. Sexually transmitted human papilloma virus (HPV) infection is the most important risk of factor for the cervical intraepithelial neoplasia or invasive cervical cancer. The worldwide incidence of the cervical cancer is approximately 510,000 new cases annually, with the approximately 288,000 deaths worldwide. Unlike many other cancers, cervical cancer occurs early or strikes at the productive period of a woman’s life. The incidence rises in the 30 to 34 years of the age or peaks at 55 to 65 years, with a median age of 38 years (age 21 to 67 years). Estimates suggest that more than 80% of the sexually active women acquire genital HPV by the 50 years of age. Hence, the advent of a vaccine against HPV has stirred much excitement as well as debate.
What is Cervical Cancer Vaccination?
The cervical cancer vaccine protects against HPV, particularly the types most commonly associated with cervical cancer (HPV types 16 and 18) and other types that cause genital warts (HPV types 6 and 11).
Types of HPV Vaccines
- Gardasil: Protects against HPV types 6, 11, 16, or 18.
- Gardasil 9: Protects against the same four types as Gardasil, plus an additional five types (31, 33, 45, 52, and 58).
- Cervarix: Protects against HPV types 16 and 18.
INDIAN SCENARIO OF HPV INFECTION
Cervical cancer is ranked of the most frequent cancer in women in the India. India has a population of the approximately 365.71 million women above 15 years of age, who are at risk of the developing cervical cancer. The current estimates indicate approximately 132,000 new cases diagnosed or 74,000 deaths annually in India, accounting to nearly 1 or 3rd of the global cervical cancer deaths. Indian women face a 2.5% cumulative lifetime risk and 1.4% cumulative death risk from the cervical cancer. At any given time, about 6.6% of the women in the general population are estimated to the harbor cervical HPV infection. HPV serotypes 16 and 18 account for nearly 76.7% of cervical cancer in India. Warts have been reported in 2–25% of sexually transmitted to the disease clinic attendees in India; however, there is no data on the burden of anogenital warts in the general community. There are currently several cervical cancer research programmes in the India. The National cancer registry programme, established by the Indian council of medical research, acts as a surveillance system for the cancer in India. It collects data in an “active” manner, visiting government and private sector hospitals, specialized cancer hospitals or pathology laboratories to get information on the types and magnitude of the cancer cases. The cancer registry in India does not cover to the entire country actively but collects information only from a few urban and rural registries established in the country.
Who Should Not Get Vaccinated?
- Adolescent Girls and Boys: Recommended for preteens aged 11-12 years but can be given as early as 9 years.
- Catch-Up Vaccination: For males and females up to the age of 26 who were not vaccinated earlier.
- Special Cases: People up to 45 years can get the vaccine after consulting with their healthcare provider. Book Your Appointment
Vaccine Schedule
- Two-Dose Schedule: For those who start the series before their 15th birthday.
- Three-Dose Schedule: For those who start the series on or after their 15th birthday and for individuals with certain immunocompromising conditions. Visit Our Hospital!